N-[6-(3,5-dimethyl-pyrazol-1-yl)-2-(5-methyl-furan-2-yl)-pyrimidin-4-yl]-2-(3-formyl-phenoxy)-acetamide | 944704-44-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-[6-(3,5-dimethyl-pyrazol-1-yl)-2-(5-methyl-furan-2-yl)-pyrimidin-4-yl]-2-(3-formyl-phenoxy)-acetamide
• 英文别名: N-[6-(3,5-dimethylpyrazol-1-yl)-2-(5-methylfuran-2-yl)pyrimidin-4-yl]-2-(3-formylphenoxy)acetamide
• CAS: 944704-44-3
• 化学式: C₂₃H₂₁N₅O₄
• 分子量: 431.451
• InChiKey: YLOOBBVIEYBXQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  112
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-[6-(3,5-dimethyl-pyrazol-1-yl)-2-(5-methyl-furan-2-yl)-pyrimidin-4-yl]-2-(3-formyl-phenoxy)-acetamide 在 吡啶 、 硼烷 、 氨 作用下， 以 乙醇 为溶剂， 生成 2-(3-(aminomethyl)phenoxy)-N-(6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methylfuran-2-yl)pyrimidin-4-yl)acetamide
  参考文献：
  名称：

  Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists

  摘要：

  A series of N-pyrimidinyl-2-phenoxyacetamide adenosine A(2A) antagonists is described. SAR studies led to compound 14 with excellent potency ( K-i = 0.4 nM), selectivity ( A(1)/A(2A) > 100), and efficacy ( MED 10 mg/ kg po) in the rat haloperidol- induced catalepsy model for Parkinson's disease. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.02.032
• 作为产物：
  描述：

  2-chloro-N-[6-(3,5-dimethylpyrazol-1-yl)-2-(5-methylfuran-2-yl)pyrimidin-4-yl]acetamide 、 间羟基苯甲醛 在 四丁基碘化铵 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-[6-(3,5-dimethyl-pyrazol-1-yl)-2-(5-methyl-furan-2-yl)-pyrimidin-4-yl]-2-(3-formyl-phenoxy)-acetamide
  参考文献：
  名称：

  Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists

  摘要：

  A series of N-pyrimidinyl-2-phenoxyacetamide adenosine A(2A) antagonists is described. SAR studies led to compound 14 with excellent potency ( K-i = 0.4 nM), selectivity ( A(1)/A(2A) > 100), and efficacy ( MED 10 mg/ kg po) in the rat haloperidol- induced catalepsy model for Parkinson's disease. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.02.032

文献信息

• WO2007/84914
  申请人：——

  公开号：——

  公开（公告）日：——
• PHENOXY-SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS
  申请人：NEUROCRINE BIOSCIENCES, INC.

  公开号：EP1976851A2

  公开（公告）日：2008-10-08
• [EN] PHENOXY-SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] PYRIMIDINES SUBSTITUEES PAR UN GROUPE PHENOXY EN TANT QU'ANTAGONISTES DES RECEPTEURS D'ADENOSINE
  申请人：NEUROCRINE BIOSCIENCES INC

  公开号：WO2007084914A2

  公开（公告）日：2007-07-26

  [EN] Compounds of formula (I), including pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof thereof, wherein R¹, R², R³, R⁴, R⁵, X, m and n are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.
  [FR] La présente invention concerne des composés répondant à la formule (I), comprenant des sels pharmaceutiquement acceptables, des esters, des solvates, des stéréoisomères et des promédicaments de ceux-ci, dans laquelle R¹, R², R³, R⁴, R⁵, X, m et n sont tels que définis dans le présent document. La présente invention concerne également des compositions pharmaceutiques contenant un composé répondant à la formule (I), ainsi que des procédés se rapportant à l'utilisation de ceux-ci.
• Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists
  作者：Xiaohu Zhang、Jaimie K. Rueter、Yongsheng Chen、Manisha Moorjani、Marion C. Lanier、Emily Lin、Raymond S. Gross、John E. Tellew、John P. Williams、Sandra M. Lechner、Stacy Markison、Tanya Joswig、Siobhan Malany、Mark Santos、Julio C. Castro-Palomino、Marı´a I. Crespo、Maria Prat、Silvia Gual、José-Luis Díaz、John Saunders、Deborah H. Slee

  DOI：10.1016/j.bmcl.2008.02.032

  日期：2008.3

  A series of N-pyrimidinyl-2-phenoxyacetamide adenosine A(2A) antagonists is described. SAR studies led to compound 14 with excellent potency ( K-i = 0.4 nM), selectivity ( A(1)/A(2A) > 100), and efficacy ( MED 10 mg/ kg po) in the rat haloperidol- induced catalepsy model for Parkinson's disease. (C) 2008 Elsevier Ltd. All rights reserved.